Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 18, 2003 | Imatinib Mesylate | FDA US | Acute Lymphoblastic Leukemia | Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with… | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib Mesylate | FDA US | Acute Lymphoblastic Leukemia | Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | cancer not stated in this record | Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. •… | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Malignant Gastrointestinal Stromal Tumor | Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase… | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Aggressive Systemic Mastocytosis | Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Myelodysplastic/Myeloproliferative Neoplasm | Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR)… | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Acute Lymphoblastic Leukemia | Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with… | ORIGNDA021588 | approved | openfda |
| Apr 18, 2003 | Imatinib | FDA US | Acute Lymphoblastic Leukemia | Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). | ORIGNDA021588 | approved | openfda |
| Apr 15, 2003 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFOSFAMIDE FOR INJECTION (DIN 02246565) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug… | DIN02246565 | withdrawnsource: Cancelled Post Marketsince Aug 29, 2024 | health-canada-dpd |
| Apr 11, 2003 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2003-04-11 (see label) | SUPPLNDA021083 | approved | openfda |
| Apr 11, 2003 | Sirolimus | FDA US | cancer not stated in this record | Efficacy supplement 2003-04-11 (see label) | SUPPLNDA021110 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 14, 2003 | Interferon Beta-1b | FDA US | cancer not stated in this record | Efficacy supplement 2003-03-14 (see label) | SUPPLBLA103471 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2003 | Interferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2003-01-31 (see label) | SUPPLBLA103628 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 3, 2002 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2002-12-03 (see label) | SUPPLBLA103964 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 16, 2002 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) • Adult Patients: In… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2002 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARA (DIN 02246226) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product Database —… | DIN02246226 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 28, 2002 | Trastuzumab | FDA US | cancer not stated in this record | Efficacy supplement 2002-08-28 (see label) | SUPPLBLA103792 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 24, 2002 | Leuprolide | FDA US | Malignant Prostate Neoplasm | VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated… | ORIGNDA021379 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 16, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-05-16 (see label) | SUPPLNDA020990 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 25, 2002 | Fulvestrant | FDA US | Malignant Breast Neoplasm | HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease… | ORIGNDA021344 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| Mar 11, 2003 | Temozolomide | FDA US | cancer not stated in this record | Efficacy supplement 2003-03-11 (see label) | SUPPLNDA021029 | approved | openfda |
| Feb 26, 2003 | Letrozole | FDA US | cancer not stated in this record | Efficacy supplement 2003-02-26 (see label) | SUPPLNDA020726 | approved | openfda |
| Feb 25, 2003 | Carmustine | FDA US | cancer not stated in this record | Efficacy supplement 2003-02-25 (see label) | SUPPLNDA020637 | approved | openfda |
| Feb 13, 2003 | Leuprolide | FDA US | Malignant Prostate Neoplasm | VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated… | ORIGNDA021488 | approved | openfda |
| Feb 7, 2003 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2003-02-07 (see label) | SUPPLNDA020990 | approved | openfda |
| Feb 7, 2003 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2003-02-07 (see label) | SUPPLNDA019839 | approved | openfda |
| Jan 17, 2003 | Letrozole | FDA US | cancer not stated in this record | Efficacy supplement 2003-01-17 (see label) | SUPPLNDA020726 | approved | openfda |
| Nov 12, 2002 | Interferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2002-11-12 (see label) | SUPPLBLA103628 | approved | openfda |
| ORIGBLA103964 |
| approved |
| openfda |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 20, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-20 (see label) | SUPPLNDA020990 | approved | openfda |
| Sep 20, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-20 (see label) | SUPPLNDA020990 | approved | openfda |
| Sep 20, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-20 (see label) | SUPPLNDA019839 | approved | openfda |
| Sep 20, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-20 (see label) | SUPPLNDA019839 | approved | openfda |
| Sep 17, 2002 | Irbesartan | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-17 (see label) | SUPPLNDA020757 | approved | openfda |
| Sep 5, 2002 | Anastrozole | FDA US | cancer not stated in this record | Efficacy supplement 2002-09-05 (see label) | SUPPLNDA020541 | approved | openfda |
| Aug 22, 2002 | Pegfilgrastim | EMA EU | cancer not stated in this record | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for… | centralisedEMEA/H/C/000422 | withdrawnsince Dec 5, 2008 | ema |
| Aug 22, 2002 | Pegfilgrastim | EMA EU | cancer not stated in this record | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for… | centralisedEMEA/H/C/000420 | approved | ema |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246030) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246030 | withdrawnsource: Cancelled Post Marketsince Apr 4, 2017 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246029) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246029 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246028) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246028 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246027) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246027 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246026) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246026 | withdrawnsource: Cancelled Post Marketsince Apr 4, 2017 | health-canada-dpd |
| approved |
| openfda |
| Jul 2, 2002 | Carmustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLIADEL WAFER (DIN 02238985) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database… | DIN02238985 | withdrawnsource: Cancelled Post Marketsince Mar 2, 2015 | health-canada-dpd |
| May 16, 2002 | Sertraline | FDA US | cancer not stated in this record | Efficacy supplement 2002-05-16 (see label) | SUPPLNDA019839 | approved | openfda |
| May 10, 2002 | Tretinoin | FDA US | cancer not stated in this record | Efficacy supplement 2002-05-10 (see label) | SUPPLNDA020475 | approved | openfda |
| May 1, 2002 | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as COPAXONE (DIN 02245619) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product… | DIN02245619 | approvedsource: Marketed | health-canada-dpd |
| approved |
| openfda |
| Apr 25, 2002 | Fulvestrant | FDA US | Malignant Breast Neoplasm | HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial… | ORIGNDA021344 | approved | openfda |